Evaluate Veterans With MGUS for Cardiovascular Disease

Monoclonal gammopathy of undetermined significance (MGUS) is not considered a hematological condition of concern, yet it is associated with lower overall survival. VA researchers led by Lawrence Liu, MD, of the St. Louis VAMC, explored whether the reduced life expectancy arose from an increased risk of cardiovascular events.

GLP-1 Use Reduces Risk of MGUS Progression in Some Veterans

Glucagon-like peptide 1 (GLP-1) receptor agonists have gained huge popularity as they have demonstrated the ability to substantially reduce both blood-glucose levels and weight. In addition, recent research suggests cardiovascular and renal benefits to their use in certain populations.

Strict LDL-C Lowering Linked to Diabetes Progression

While some guidelines recommend statin use to achieve low-density lipoprotein cholesterol (LDL-C) goal under 70 mg/dL for primary prevention of atherosclerotic cardiovascular disease (ASCVD) in patients at higher risk, others recommend against a target LDL-C level.

Repository Offers Clues About Young Adult Classical HL

Immune abnormalities persist in young adult classical Hodgkin lymphoma (YAcHL) patients long after cure. Yet, new research presented at the most recent Annual ASH Meeting and Exposition in New Orleans pointed out the difficulties in assessing whether those issues existed prior to diagnosis.

Hemorrhagic Mortality A Problem for APL Patients

Even though the rate of complete remission of acute promyelocytic leukemia (APL) is currently more than 90% because of the use of all-trans retinoic acid (ATRA) with arsenic trioxide (ATO), hemorrhagic mortality has emerged as the most significant barrier to APL-induced remission, according to a new study.